Jim Simons
GTBP icon

Jim Simons’s GT Biopharma GTBP Stock Holding History

Jim Simons’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,300
Closed -$94.2K – 3650
2025
Q2 		$94.2K Buy
+26,300
New +$68K ﹤0.01% 3306
2024
Q1 		– Sell
-3,823
Closed -$29K – 3852
2023
Q4 		$29K Buy
3,823
+1,600
+72% +$11.7K ﹤0.01% 3535
2023
Q3 		$16K Sell
2,223
-850
-28% -$7.03K ﹤0.01% 3546
2023
Q2 		$29K Buy
3,073
+760
+33% +$7.88K ﹤0.01% 3706
2023
Q1 		$38K Buy
2,313
+773
+50% +$17.7K ﹤0.01% 3714
2022
Q4 		$41K Buy
+1,540
New +$76.9K ﹤0.01% 3835
2022
Q3 		– Sell
-2,157
Closed -$193K – 4166
2022
Q2 		$193K Sell
2,157
-4,053
-65% -$307K ﹤0.01% 3666
2022
Q1 		$537K Sell
6,210
-4,013
-39% -$354K ﹤0.01% 3140
2021
Q4 		$935K Buy
10,223
+7,400
+262% +$1.11M ﹤0.01% 2696
2021
Q3 		$571K Buy
+2,823
New +$850K ﹤0.01% 2838

Other funds holding GTBP

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Jim Simons's GTBP Position: Q3 2025 in Review

Jim Simons sold out of GT Biopharma (GTBP) in Q3 2025, closing a stake of 26,300 shares — an estimated $94.2K sold.

Jim Simons first reported a position in GTBP in Q3 2021 and held it in 10 quarters. The position peaked at $935K in Q4 2021. 21 funds tracked by Wall St. Rank hold GTBP as of Q3 2025.

  • Jim Simons reported no remaining GT Biopharma position as of Q3 2025 after selling out during the quarter.
  • Jim Simons sold 26,300 GT Biopharma shares in Q3 2025, an estimated $94.2K.
  • Jim Simons first reported a position in GT Biopharma in Q3 2021 and held it in 10 quarters.
  • Jim Simons's GT Biopharma position peaked at $935K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.